Diuretic–gene interaction and the risk of myocardial infarction and stroke

被引:1
|
作者
H Schelleman
O H Klungel
J C M Witteman
M M B Breteler
A Hofman
C M van Duijn
A de Boer
B H Ch Stricker
机构
[1] Erasmus MC,Department of Epidemiology & Biostatistics
[2] Utrecht Institute for Pharmaceutical Sciences (UIPS),Department of Pharmacoepidemiology and Pharmacotherapy
[3] Utrecht University,undefined
来源
The Pharmacogenomics Journal | 2007年 / 7卷
关键词
pharmacogenetics; diuretics; polymorphisms; MI; stroke;
D O I
暂无
中图分类号
学科分类号
摘要
This study investigates whether the interaction between diuretics and alpha-adducin (ADD1) G460W or G-protein β3-subunit (GNB3) rs2301339 polymorphism modifies the risk of myocardial infarction (MI) or stroke. Data were used from the Rotterdam Study. The drug–gene interaction was determined with a Cox proportional hazard model with adjustment for each drug class as time-dependent covariates. The risk of MI in current users of low-ceiling diuretics with one or two copies of the ADD1 W-allele (hazard ration (HR)=0.92) was similar compared to the expected joint effect of the W-allele and low-ceiling diuretics on a multiplicative scale (1.04 × 0.90=0.94) (synergy index (SI):0.99; 95% confidence interval (CI): 0.43–2.27). No drug–gene interaction was found on the risk of stroke (SI:0.66; 95% CI:0.43–1.27). In addition, a trend towards an interaction was found between current use and the GNB3 rs230119 G/A polymorphism on the risk of MI (SI: 0.51; 95% CI: 0.23–1.15), whereas no interaction on the risk of stroke was found (SI: 0.84; 95% CI: 0.46–1.56).
引用
收藏
页码:346 / 352
页数:6
相关论文
共 50 条
  • [41] Risk for stroke and myocardial infarction with abiraterone versus enzalutamide in metastatic prostate cancer patients
    Kulkarni, A. A.
    Rubin, N.
    Tholkes, A.
    Shah, S.
    Ryan, C. J.
    Lutsey, P. L.
    Prizment, A.
    Rao, A.
    ESMO OPEN, 2021, 6 (05)
  • [42] Is gout a risk equivalent to diabetes for stroke and myocardial infarction? A retrospective claims database study
    Jasvinder A. Singh
    Rekha Ramachandaran
    Shaohua Yu
    Shuo Yang
    Fenglong Xie
    Huifeng Yun
    Jie Zhang
    Jeffrey R. Curtis
    Arthritis Research & Therapy, 19
  • [43] Reducing the risk for stroke in patients with myocardial infarction - A Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy
    Gotto, AM
    Farmer, JA
    CIRCULATION, 2002, 106 (13) : 1595 - 1598
  • [44] Coagulation factor XIII polymorphisms and the risk of myocardial infarction and ischaemic stroke in young women
    Reiner, AP
    Frank, MB
    Schwartz, SM
    Linenberger, ML
    Longstreth, WT
    Teramura, G
    Rosendaal, F
    Psaty, BM
    Siscovick, DS
    BRITISH JOURNAL OF HAEMATOLOGY, 2002, 116 (02) : 376 - 382
  • [45] Heart failure on admission and the risk of stroke following acute myocardial infarction: the VALIANT registry
    Szummer, KE
    Solomon, SD
    Velazquez, EJ
    Kilaru, R
    McMurray, J
    Rouleau, JL
    Mahaffey, KW
    Maggioni, AP
    Califf, RM
    Pfeffer, MA
    White, HD
    EUROPEAN HEART JOURNAL, 2005, 26 (20) : 2114 - 2119
  • [46] Prospective study of herpes simplex virus, cytomegalovirus, and the risk of future myocardial infarction and stroke
    Ridker, PM
    Hennekens, CH
    Stampfer, MJ
    Wang, F
    CIRCULATION, 1998, 98 (25) : 2796 - 2799
  • [47] Alteplase: descendancy in myocardial infarction, ascendancy in stroke
    Doggrell, SA
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (11) : 2013 - 2029
  • [48] Stroke and myocardial infarction after herpes zoster
    Wutzler P.
    MMW - Fortschritte der Medizin, 2017, 159 (13) : 66 - 68
  • [49] Immunosuppressive Treatments in Acute Myocardial Infarction and Stroke
    Raffaghello, Lizzia
    Bianchi, Giovanna
    Pistoia, Vito
    CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2012, 13 (01) : 59 - 67
  • [50] Ischemic stroke - Impact of a recent myocardial infarction
    Mooe, T
    Olofsson, BO
    Stegmayr, B
    Eriksson, P
    STROKE, 1999, 30 (05) : 997 - 1001